With its new anti-epileptic drug cenobamate now under review in Europe, Arvelle Therapeutics GmbH is doing the groundwork for the commercial launch that should turn the Swiss biotech into a fully integrated pharmaceutical company.
Interview: Arvelle Aims To Be Major Player In CNS
Epilepsy Drug Cenobamate Filed in Europe
The Swiss biotech's focal-onset seizure therapy, which is licensed from South Korea's SK and is already approved in the US, could have potential in indications beyond epilepsy, Arvelle's CEO tells Scrip.
More from Neurological
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.